Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.56 |
| ▸ | MC4R | P32245 | 8/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449964 | 1.00 | IL23R (0.56) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL28714609 | 0.97 | IL23R (0.56) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL30464987 | 0.94 | IL23R (0.57) | IL23RMC4RKISS1R | |
| SCHEMBL647795 | 0.92 | MC4R (0.51) | IL23RMC4RKISS1R | |
| SCHEMBL14117706 | 0.92 | MC4R (0.55) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL29973259 | 0.92 | GLP1R (0.52) | IL23RMC4R | |
| SCHEMBL18891483 | 0.92 | MC4R (0.62) | IL23RMC4RKISS1R | |
| SCHEMBL18891548 | 0.92 | MC4R (0.62) | IL23RMC4RKISS1R | |
| SCHEMBL30464997 | 0.89 | IL23R (0.57) | IL23RMC4RKISS1R | |
| SCHEMBL30464993 | 0.89 | IL23R (0.58) | IL23RMC4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3487862-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | Bristol-Myers Squibb Company (US) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018017910-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9174965-B2 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| WO-2015061272-A1 | ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2010009183-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2144902-A1 | [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012277-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | IL23R 1715/4885MC4R 317/4885KISS1R 518/4885 |
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | IL23R 4346/4885MC4R 1129/4885KISS1R 1887/4885 |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | IL23R 926/4885MC4R 112/4885KISS1R 239/4885 |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | IL23R 976/4885MC4R 172/4885KISS1R 410/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | IL23R 1526/4885MC4R 333/4885KISS1R 634/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | IL23R 4346/4885MC4R 1129/4885KISS1R 1887/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | IL23R 1709/4885MC4R 333/4885KISS1R 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.